Summary
The objective of this phase-I study was to establish the maximum tolerable dose of recombinant human interleukin-3 (rhIL-3) after salvage chemotherapy in patients with malignant lymphoma. Twenty-one patients with relapsed Hodgkin's disease or intermediate/high-grade non-Hodgkin's lymphoma received rhIL-3 after the second cycle of DHAP chemotherapy (cisplatin, cytosine-arabinoside, dexamethasone). Cycles 1 and 3 were given without rhIL-3. The rhIL-3 was administered as a continuous intravenous infusion for 10 days starting 48 h after chemotherapy in cycle 2. Five different dose levels of rhIL-3 (0.25, 1.0, 2.5, 5.0, and 10.0μg/kg/day) were sequentially tested. At the three lowest dose levels one double-blinded placebo was included for every four patients per dose level. Low-grade fever occurred in 15/21 patients, unrelated to the dose of rhIL-3. Nausea and vomiting (grade 1–2) occurred in seven patients. Headache was dose related, with 3/4 patients at a dose of 10μg/kg/day experiencing troublesome grade-2 headache precluding further dose escalation. Facial flushing developed in 3/8 patients at the highest dose levels of rhIL-3. There was a significant increase in eosinophil count during rhIL-3 (p=0.03 cycle 2 vs cycle 1 andp=0.002 cycle 2 vs cycle 3) without accompanying clinical signs or symptoms. No increase in basophil count was observed. There were no increased plasma levels of interleukin-6 or macrophage colony-stimulating factor (M-CSF) during rhIL-3. We conclude that rhIL-3 can be safely administered as a continuous intravenous infusion for 10 days after DHAP chemotherapy. Dose-limiting side effects, especially headache, occur at a dose of 10μg/kg/day.
Similar content being viewed by others
References
Ihle JN, Keller J, Oroszlan S, et al. (1983) Biological properties of homogeneous interleukin-3. I. Demonstration of WEHI-3 growth factor activity, mast cell growth factor activity, P cell stimulating factor activity, colony-stimulating activity and histamine-producing cell-stimulating factor activity. J Immunol 131:282–287
Leary AG, Yang Y-C, Clark SC, et al. (1987) Recombinant gibbon interleukin-3 supports the formation of human multilineage colonies and blast cell colonies in culture: comparison with recombinant human granulocyte-macrophage stimulation factor. Blood 70:1343–1348
Emerson SG, Yang YC, Clark SC, et al. (1988) Human recombinant granulocyte-macrophage colony stimulating factor and interleukin-3 have overlapping but distinct hematopoietic activities. J Clin Invest 82:1282–1287
Cannistra SA, Vellenga E, Groshek P, et al. (1988) Human granulocyte-monocyte colony-stimulating factor and interleukin-3 stimulate cytotoxicity through a tumor necrosis factordependent mechanism. Blood 71:672–767
Lopez AF, To LB, Yang YC, et al. (1987) Stimulation of proliferation, differentiation and function of human cells by primate interleukin 3. Proc Natl Acad Sci USA 84:2761–2765
Oster W, Lindeman A, Mertelsmann R, et al. (1989) Granulocyte-macrophage colony-stimulating factor (CSF) and multilineage CSF recruit human monocytes to express granulocyte CSF. Blood 73:64–67
Hirai K, Morita Y, Misaki Y, et al. (1988) Modulation of human basophil histamine release by hematopoietic growth factors. J Immunol 141:3958–3964
Kurzrock R, Talpaz M, Estrov E, et al. (1991) Phase-I study of recombinant human interleukin-3 in patients with bone marrow failure. J Clin Oncol 9:1241–1250
Ganser A, Lindemann A, Seipelt G, et al. (1990) Effects of recombinant human interleukin-3 in patients with normal hematopoiesis and in patients with bone marrow failure. Blood 76:666–676
Lindemann A, Ganser A, Herrmann F, et al. (1991) Biologic effects of recombinant human interleukin-3 in vivo. J Clin Oncol 9:2120–2127
Petersen FB, Appelbaum FR, Hill R, et al. (1990) Autologous bone marrow transplantation for malignant lymphoma: a report of 101 cases from Seattle. J Clin Oncol 8:638–647
Desch CE, Lasala MR, Smith TJ, et al. (1992) The optimal timing of autologous bone marrow transplantation in Hodgkin's disease patients after a chemotherapy relapse. J Clin Oncol 10:200–209
Canellos GP (1992) The second chance for advanced Hodgkin's disease. J Clin Oncol 10:175–177 (editorial)
Velasquez WS, Cabanillas S, Salvador P, et al. (1988) Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 71:117–122
Press OW, Livingston R, Mortimer J, et al. (1991) Treatment of relapsed non-Hodgkin's lymphoma with dexamethasone, high-dose cytarabine, and cisplatin before marrow transplantation. J Clin Oncol 9:423–431
Gillio AP, Gasparetto C, Laver J, et al. (1990) Effects of interleukin-3 on hematopoietic recovery after 5-fluorouracil or cyclophosphamide treatment in cynomolgous monkeys. J Clin Invest 85:1560–1565
Postmus PE, Gietema JA, Damsma O, et al. (1992) Effects of recombinant human interleukin-3 in patients with relapsed small-cell lung cancer treated with chemotherapy: a dose-finding study. J Clin Oncol 10:1131–1140
Shadle PJ, Allen JI, Geier MD, et al. (1989) Detection of endogenous macrophage colony-stimulating factor (M-CSF) in human blood. Exp Hematol 17:154–159
Van Damme J, Cayphas S, Opdenakker G, et al. (1987) Interleukin-1 and poly(rI).poly(rC) induce production of a hybridoma growth factor by human fibroblasts. Eur J Immunol 17:1–7
Fibbe W, Raemaekers J, Verdonck L, et al. (1991) A phase-I/II trial of interleukin-3 after autologous bone marrow transplantation in patients with malignant lymphoma. Blood 78 [Suppl 1]:163a (abstract)
Wagemaker G, van Gils FCJM, Burger H, et al. (1990) Highly increased production of bone marrow-derived blood cells by administration of homologous interleukin-3 to rhesus monkeys. Blood 76:2235–2241
Metcalf D, Begley CG, Johnson GR, et al. (1986) Effects of purified bacterially synthesized murine multi-CSF (IL-3) on hematopoiesis in normal adult mice. Blood 68:46–57
Nijstein MWN, DeGroot ER, Ten Duis JH, et al. (1987) Serum levels of interleukin-6 and acute-phase responses. Lancet 2:921
Becker S, Warren MK, Haskill S (1987) Colony-stimulating factor-induced monocyte survival and differentiation into macrophages in serum-free cultures. J Immunol 139:3703–3709
Brugger W, Bross KJ, Frisch J, et al. (1992) Mobilization of blood progenitor cells by sequential administration of IL-3 and GM-CSF following chemotherapy with etoposide, ifosfamide and cisplatin. Blood 79:1193–1200
Author information
Authors and Affiliations
Additional information
This study was supported by Sandoz Pharma, Basel, Switzerland
Rights and permissions
About this article
Cite this article
Raemaekers, J.M.M., van Imhoff, G.W., Verdonck, L.F. et al. The tolerability of continuous intravenous infusion of interleukin-3 after DHAP chemotherapy in patients with relapsed malignant lymphoma. Ann Hematol 67, 175–181 (1993). https://doi.org/10.1007/BF01695864
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01695864